In their study, tumor-infiltrating FOXP3+ Tregs are much rarer in non-upper aerodigestive tract (UAT)-NKTCLs than in UAT-NKTCLs and in patients with poor performance status (PS), which might lead to poor clinical outcome of patients with decreased Tregs. This evidence concerns the gene FOXP3 and neoplasm.